|
|
 |
|
Viewing report
|
|
|
|
The Obama Administration and the Pharmaceutical Industry - Overview of the 2009 Recovery Act and the 2010 Federal Budget
CBR Pharma Insights, June 2009
President Obama has made healthcare reform one of his administration’s top priorities. Towards this goal, several billion dollars have been provided through the Recovery Act and 2010 Budget for initiatives that are intended to make the US healthcare system safer and more cost-effective.
These include:
- conducting comparative effectiveness research trials to help physicians and patients make more informed decisions at the point-of-care;
- adopting health information technologies, such as ePrescribing, telemedicine and electronic medical records (EMR);
- expanding Medicaid and strengthening Medicare by focusing on program integrity issues;
- promoting more affordable drug options by expediting the approval of generic drugs and opening the market to consumers who would like to buy drugs from neighboring countries.
Healthcare reforms like these are all going to have a significant impact on the pharmaceutical industry’s bottom line. This report discusses the upcoming and proposed reforms in detail, and includes information on how these changes will impact the pharmaceutical industry in the US.
Reasons to Purchase
Use this report to:
- Learn how the Recovery Act of 2009 and the Fiscal Year 2010 Federal Budget will be used to enact change to the current US Healthcare System
- Understand the 4 key areas of focus for healthcare reform highlighted by the Obama Administration and their impact on the pharmaceutical industry
- Gain insights into how the pharmaceutical industry should approach the challenges that will ensue with comparative effectiveness research (CER)
- Understand the advantages and barriers to Health IT, as well as its impact on the pharmaceutical industry
- Find out how the current budget proposal could affect pharmaceutical drug pricing & project safety, along with changes to the government sponsored programs – Medicare & Medicaid
- Benefit from our conclusions and future outlook to best support your understanding and key decisions around the potential changes to the pharmaceutical industry as a result of US healthcare reform
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Obama's Healthcare Reform Bill and its Impact on the U.S. Healthcare Market
Pharmaceutical Pricing, Reimbursement, and Market Access News in the First Quarter of 2011
Market Access in the United States: An Uncertain Outlook
Pharmaceutical Pricing, Reimbursement, and Market Access News in the Second Quarter of 2011
US Healthcare Reform: Impact and Implications for the Pharmaceutical and Biotech Industries
U.S. Healthcare Reform: Impact on the Pharmaceutical Industry
Impact of US Healthcare Reforms - the Extension of Care to 32 Million Uninsured Citizens from 2014 and Implications for the Pharmaceutical Industry
The 111th U.S. Congress Tackles Healthcare Reform and the Pharmaceutical Industry
Pharma Pricing and Reimbursement Outlook: Optimizing Price and Market Access in a Recessionary Climate
Pharmaceutical Pricing, Reimbursement, and Market Access News in the Third Quarter of 2011
|
|
|
|
